Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Dexamethasone
Related studies linked through entity extraction aliases.
Is Insulin Resistance and/or Glucose Intolerance Pathogenetic in the Development of a Reduced Incretin Effect
- Status
- COMPLETED
- Phase
- NA
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
- Status
- COMPLETED
- Phase
- PHASE2
Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)
- Status
- COMPLETED
- Phase
- PHASE2
Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095)
- Status
- COMPLETED
- Phase
- PHASE2
Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)
- Status
- COMPLETED
- Phase
- PHASE3
Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
- Status
- UNKNOWN
- Phase
- PHASE3
Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive
- Status
- COMPLETED
- Phase
- PHASE2
Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
- Status
- UNKNOWN
- Phase
- PHASE2
Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Safety/Efficacy of Antibiotic Steroid Combination in Treatment of Blepharitis and/or Keratitis and/or Conjunctivitis
- Status
- COMPLETED
- Phase
- PHASE3
Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia
- Status
- WITHDRAWN
- Phase
- PHASE2
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function
- Status
- TERMINATED
- Phase
- PHASE2
Effectivity of Postpartum Dexamethasone for Women With Class I HELLP Syndrome
- Status
- TERMINATED
- Phase
- PHASE4
Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2